P21
CNTF-Derived Neurogenic Peptide | Cognitive Enhancement & Neuroprotection
On this page
What is P21?
P21 is a lab-made, modified peptide based on a small active fragment of human ciliary neurotrophic factor (CNTF), engineered for better absorption through the nose and into the brain. It has been studied in animal models for effects on neuron growth, memory, and recovery after brain injury, but no human clinical trials have been conducted. It's supplied here strictly as a research chemical for laboratory study, not for human or animal use.
Key terms:
P21 is a synthetic modified tetrapeptide derivative.
P21 (also called P021) is a lab-made four-amino-acid peptide. Its sequence comes from the biologically active region of human ciliary neurotrophic factor (CNTF), a nerve-cell survival protein. An adamantylated glycine modification helps it cross the blood-brain barrier and resist breakdown. In preclinical models, researchers reported P21 promoted neurogenesis (new nerve-cell growth), enhanced synaptic plasticity, and gave significant cognitive benefits. Those models covered Alzheimer's disease, traumatic brain injury, and age-related cognitive decline.
Key research areas
- Rapid CNS delivery via olfactory and trigeminal nerve pathways
- Bypasses hepatic first-pass metabolism
- Potentially lower doses needed compared to subcutaneous
- Non-invasive administration
- May provide more pronounced acute cognitive effects
Researched dosing
This table reflects the dose ranges reported in P21 research protocols, presented as research-methodology reference, not personal usage instructions.
| Phase | Dose | Frequency | Route |
|---|---|---|---|
| Cognitive-performance studies | 500mcg-1mg | 1x daily | Intranasal |
| Acute cognitive studies | 1-2mg | As needed | Intranasal |
| Maintenance and neuroprotection | 500mcg | 1x daily | Intranasal |
| Initial assessment | 500mcg | 1x daily | Intranasal |
Commonly cycled 6 weeks on, 2+ weeks off.
How it works
At the cell level, P21 research looks at how the peptide travels from the nose to the brain and appears to support new neuron growth and connections between brain cells — the terms below name those cellular signaling steps.
Intranasal administration exploits the direct anatomical connection between nasal mucosa and brain via olfactory and trigeminal nerve pathways. This provides rapid CNS delivery while minimizing systemic exposure. P21's lipophilic adamantane modification enhances mucosal absorption and subsequent brain penetration.
Molecular data
These figures — molecular weight, short amino-acid sequence, chemical modification — are the chemistry ID researchers use to confirm a P21 sample's identity; a lab-added modification is what helps it cross into brain tissue more easily.
- Weight
- 578.3 Da
- Length
- 5 amino acids
- Type
- Modified tetrapeptide derivative
Ac-DGGLAG-NH2
Pharmacokinetics
This chart shows how a research dose of P21 is absorbed and cleared in the reported animal data — read it like a timer: it peaks quickly, then gradually clears over several hours.
- Peak
- 0.25 hr
- Half-life
- 6 hrs
- Cleared
- ~31.2 hrs
Li et al. FEBS Lett 2010
Research applications
This section lists the research areas — memory, learning, and neuron growth — that scientists have studied for P21 in animal models; it's a summary of preclinical and anecdotal findings, not medical claims about people, and no human clinical trials have been conducted.
Cognitive
Intranasal route may provide faster onset of cognitive effects compared to subcutaneous administration due to direct CNS delivery. Users report enhanced focus, mental clarity, and sustained attention with intranasal P21 administration. Enhanced memory consolidation and recall through direct hippocampal access via nasal route.
Neuroprotective
P21 promotes neurogenesis, enhances synaptic plasticity, and has shown significant neuroprotective benefits in preclinical models of Alzheimer's disease and traumatic brain injury.
Mood
Preclinical and anecdotal data suggest mood-related benefits through neuroplasticity and BDNF pathway activation.
Dosage reference
- Doses used in research
- 500 mcg to 1 mg
- Frequency in studies
- 1-2x daily
- Handling
- Reconstituted solution — research use only; not for administration
- Timeline reported in studies
- Minutes to hours for acute effects, weeks for sustained benefits
- Storage
- Fridge 2-8°C, use within 14-21 days
- Cycle length
- 4-6 weeks
- Break between cycles
- 2-4 weeks between cycles
Interactions
This list shows which other cognitive-research peptides are studied alongside P21, and why.
Reconstitution & storage
This is the standard laboratory method for turning freeze-dried P21 powder into a nasal research solution — the same basic mixing process used for most intranasal peptide research.
- Reconstitute P21 with appropriate volume of BAC water or sterile saline
- Calculate concentration for desired dose per spray (typically 0.1mL per spray)
- Transfer reconstituted solution to clean nasal spray bottle
- Prime spray bottle before first use
- Store the reconstituted solution refrigerated (2–8°C), labeled with the date and concentration, for laboratory research use only.
Lyophilized: 2-8°C, use within Per manufacturer expiration date
Reconstituted: 2-6°C, use within 14-21 days
Open the P21 reconstitution calculatorQuality indicators
These are the checks researchers use to confirm a P21 sample is pure and correctly concentrated before it's used in a study — a quick reference against a Certificate of Analysis (COA).
Clear Nasal Solution - Reconstituted P21 for nasal use should be crystal clear with no particles or cloudiness.
Proper Spray Mechanism - Nasal spray bottle should deliver consistent, metered doses with each actuation.
Certificate of Analysis - Source peptide should have third-party testing showing high purity.
Dilution Accuracy - Ensure accurate calculation of concentration for proper dosing per spray.
Cloudy or Discolored Solution - Any cloudiness, particles, or discoloration indicates degradation or contamination.
Inconsistent Spray - Malfunctioning spray mechanism prevents accurate dosing.
What to expect
This timeline summarizes what the available animal-model and anecdotal reports describe at each stage — research context for comparing findings, not a personal-results promise.
Potential acute cognitive enhancement
Cumulative cognitive improvements
Enhanced memory and focus
Full neuroplasticity benefits
Safety notes
This section covers handling cautions and regulatory notes for P21 — it has not been tested in human clinical trials, and this entry is strictly research-use-only.
- Use sterile nasal spray equipment
- Clear nasal passages before administration
- May cause temporary nasal irritation
- CRITICAL: No human clinical trials have been conducted
- Start with lower doses to assess tolerance
- Consult healthcare provider before use
- All benefits are based on preclinical and anecdotal data
- Not FDA-approved - research chemical only with no human clinical trials
Regulatory status
- Not approved by the FDA for any indication.
- Supplied and described for laboratory research use only — not for human or veterinary use.
Community data
Community Insights
Based on data the community reported. Not clinical proof.
Frequently asked questions
What is P21 studied for in research?
P21 (also called P021) is a synthetic CNTF-derived tetrapeptide with an adamantane modification that improves stability and blood-brain-barrier penetration. Preclinical research has investigated it for neurogenesis and synaptic-plasticity pathways in models of cognitive decline. It is supplied strictly as a research-use-only reference material, not for human use.
How is P21 reconstituted for laboratory use?
P21 is reconstituted with bacteriostatic water or sterile saline to the concentration a study protocol requires. Because it is often studied intranasally in models, the solution may be calculated per spray volume. It is added gently down the vial wall, dissolved without shaking, then labeled with the date and concentration and refrigerated.
How should P21 be stored?
Lyophilized P21 is stored refrigerated at 2-8°C and protected from light. After reconstitution the solution is held near 2-6°C and used within roughly 14-21 days. Cold, dark storage limits degradation of the modified tetrapeptide across the research window; discard any solution that becomes cloudy.
How does P21 differ from Semax?
Both are studied in cognitive and neuroprotection research, but they come from different origins: P21 derives from ciliary neurotrophic factor (CNTF) and is studied for direct neurogenesis pathways, while Semax is an ACTH(4-10) fragment studied for BDNF and neuromodulatory signaling. They are distinct research reference peptides.
References
Original study demonstrating P21 (Ac-DGGLAG-NH2) enhanced learning and both short-term and spatial reference memories in normal adult mice. P21 induced enhancement of neurogenesis and maturation of newly born neurons in the dentate gyrus, increased synaptophysin and synapsin I expression.
P021 treatment significantly reduced abnormal tau hyperphosphorylation, increased BDNF expression, rescued neurogenesis deficits, and improved cognitive function in triple-transgenic Alzheimer's mice. Effects mediated via BDNF/TrkB/PI3K/AKT/GSK3β pathway.
In controlled cortical impact TBI model, Peptide 6 (P21 parent) increased newborn neurons in dentate gyrus by 80%, reversed TBI-induced dendritic and synaptic density loss, and improved memory recall on behavioral testing.